t 14

T14-A24 is an orally active, reversible, competitive, and selective AChE inhibitor with a Ki of 22 nM and an IC50 of 6 nM. It displays excellent blood-brain barrier penetration, significant neuroprotective effects, and favorable toxicological characteristics.

RORγt inverse agonist 14 (8e) is a potent, selective, and orally active compound with an EC50 of 2.5 nM, demonstrating anti-inflammatory activity. It is utilized in the research of rheumatoid arthritis and psoriasis [1].

Hydroxy-PEG14-t-butyl ester is a PEG-based PROTAC linker utilized in the synthesis of PROTAC molecules.

Azido-PEG14-t-butyl ester serves as a PROTAC linker from the PEG family, utilized in synthesizing PROTAC molecules. It acts as a click chemistry reagent containing an Azide group, enabling copper-catalyzed azide-alkyne cycloaddition reactions (CuAAC) with Alkyne-containing molecules. Additionally, it can undergo strain-promoted azide-alkyne cycloaddition (SPAAC) reactions with molecules that have DBCO or BCN groups.

Benzyl-PEG14-t-butyl-ester is a PROTAC linker part of the PEG class, used in the synthesis of PROTAC molecules.

Acid-PEG14-t-butyl ester is a PROTAC linker of the PEG category, utilized in the synthesis of PROTAC molecules.

Lipid 12T-O14 is a lipid nanoparticle that facilitates the delivery of local mRNA vaccines and systemic mRNA agents.

YT 146 is a selective adenosine receptor A2 agonist with cardioprotective and vasodilatory effects that inhibits neointimal thickening after endothelial injury in rat femoral arteries.

Antimalarial agent 14 (NSC-102533) is a bioactive chemical.

Antitrypanosomal agent 14 (Compound 1), a potent T. brucei inhibitor with an effective concentration (EC50) of 0.47 μM, also inhibits Tb GSK3 with an inhibitory concentration (IC50) of 12 μM, and is utilized in the research of Human African Trypanosomiasis [1].

EP4 antagonist 14 is a prostaglandin E2 receptor subtype EP4 antagonist, demonstrating an IC50 of 1.1 nM in a HEK293 human receptor reporter assay and blocking β-arrestin recruitment due to PGE2 with an IC50 of 0.9 nM. At 10 µM, it reduces PGE2-stimulated mRNA levels of Il-4, macrophage mannose receptor 1 (Mrc1), chitinase-like protein 3 (Chil3), chemokine (C-X-C) motif ligand 1 (Cxcl1), triggering receptor expressed on myeloid cells 2 (Trem2), and arginase-1 (Arg1) in RAW 264.7 macrophages. When used at 30 mg/kg per day alongside anti-PD-1 antibodies, it curbs tumor growth and enhances CD8+ T cell infiltration in tumors using a CT26 murine colon cancer model.

AR antagonist 14 serves as a ligand for the target protein in PROTAC applications. It can be coupled with VH 101-amide-piperidine-Pip-alkyne to synthesize the PROTAC degrader [ARD-69].

Anti-MRSA agent 14 (Compound C17) exhibits antibacterial activity against MRSA and in a MRSA-infected mouse skin model. It demonstrates greater potential against MRSA compared to Norfloxacin. Anti-MRSA agent 14 disrupts cell membranes and inhibits metabolism. Its antibacterial MIC values against S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 12228, and MRSA are 1, 2, 2, and 1 μM, respectively.

Nurr1 Agonist 14 (Compound 32) is a Nurr1 agonist with an EC50 of 0.09 μM for Nurr1. It exhibits significant neuroprotective activity without being hindered by residual DHODH inhibition. This compound can upregulate neuroprotective genes in dopaminergic neurons, such as SOD2, SESN3, BIRC5, XIAP, FLRT2, and CRMP4. Nurr1 Agonist 14 is useful for studying neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS).

Antifungal agent 14 demonstrates potent broad-spectrum antifungal activity, effectively targeting a variety of fungal strains with exceptional minimum inhibitory concentration values.

iCRT 14 is a novel and potent inhibitor of β-catenin-responsive transcription (CRT) with an IC50 of 40.3 nM in assays of Wnt pathway activity.

Anti-inflammatory agent 14 (compound 28) exhibits a MIC50 of 2 μM for Mtb H37Rv and also functions as an anti-inflammatory agent [1].

Antiviral agent 14 is an antiviral compound that inhibits tobacco mosaic virus (TMV) with an EC50 of 135.5 μg/mL and cucumber mosaic virus (CMV) with an EC50 of 178.6 μg/mL.

Anticancer agent 14 is a lead compound (IC50: 0.20-0.65 μM) that blocks the cell cycle of breast cancer cells, induces apoptosis, and causes loss of mitochondrial membrane potential.

GLP-1R agonist 14, also known as Compound 14, is a potent agonist of the GLP-1 receptor, demonstrating an EC50 range of 0-20 nM against human GLP-1 [1].

Antibacterial agent 142, an aromatic hydrazide, exhibits bacteriostatic antibacterial activity and inhibits biofilm formation [1].

Compound 5a (Antibacterial agent 143) is an antibacterial agent exhibiting minimum inhibitory concentrations (MICs) of 25 μg/mL against B. subtilis ATCC6633 and S. aureus ATCC6538, and 50 μg/mL against P. aeruginosa ATCC13525 and E. coli ATCC35218, demonstrating its effectiveness in inhibiting bacterial growth [1].

Compound 1b, also known as Antibacterial agent 145, targets the bacterial iron uptake pathway to exert its effects. It compromises the integrity of the bacterial cytoplasmic membrane and inhibits cellular metabolism while demonstrating minimal cytotoxicity to normal cells [1].

Antibacterial agent 140 chloride, a first-of-its-kind Ru-based AIEgen photosensitizer, shows promise in detecting and treating Gram-positive bacteria (G+). It effectively discriminates against and exterminates G+ by interacting with lipoteichoic acids (LTA), displaying robust antibacterial activity under light irradiation [1].